Factors implicated in the generation and persistence of long-lived plasma cell-mediated autoimmunity

Autoimmunity Reviews

Volumn 10, Issue 7, 2011, Pages 375-382

  Neves, Marisa ^a   Alves, José Delgado ^a,b  

^a HOSPITAL FERNANDO FONSECA   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Long lived plasma cells; Survival niches; Therapeutic targets

Indexed keywords

AUTOANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CELL TYPE; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PLASMA CELL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; PLASMA CELLS;

EID: 79955094058     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.12.007     Document Type: Review

References (105)

1. Hoyer B.F., Mumtaz I.M., Yoshida T., Hiepe F., Radbruch A. How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann Rheum Dis 2008, 67:iii87-iii89.
2. Moser K., Muehlinghaus G., Manz R., Mei H., Voigt C., Yoshida T., et al. Long-lived plasma cells in immunity and immunopathology. Immunol Lett 2006, 103:83-85.
3. Tarlinton D.M., Hodgkin P.D. Targeting plasma cells in autoimmune diseases. J Exp Med 2004, 199:1451-1454.
4. Moser K., Tokoyoda K., Radbruch A., McLennan I., Manz R. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006, 18:265-270.
5. Fairfax K.A., Kallies A., Nutt S.L., Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol 2008, 20:49-58.
6. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature 2006, 5:564-576.
7. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G.C., Dörner T., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nature 2006, 6:741-750.
8. Duan B., Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006, 6:403-408.
9. Milner E.C., Anolik J., Cappione A., Sanz I. Human innate B cells: a link between host defence and autoimmunity?. Springer Semin Immunopathol 2005, 26:433-452.
10. Fairfax K., Corcoran L.M., Pridans C., Huntington N.D., Kallies A., Nutt S.L., et al. Different Kinetics of Blimp-1 Induction in B Cell Subsets Revealed by Reporter Gene. J Immunol 2007, 178:4104-4111.
11. Gatto D., Pfister T., Jegerlehner A., Martin S.W., Kopf M., Bachmann M.F. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 2005, 201:993-1005.
12. Mongini P.K.A., Jackson A.E., Tolani S., Fattah R.J., Inman JK J.K. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. J Immunol 2003, 171:5244-5254.
13. Pugh-Bernard A.E., Silverman G.J., Cappione A.J., Villano M.E., Ryan D.H., Insel R.A., et al. Regulation of inherently autoreactive VH4-43 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001, 108:1061-1070.
14. Arons E., Suntum T., Stetler-Stevenson M., Kreitman R.J. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009, 114:4687-4695.
15. Pascual V., Victor K., Spellerberg M., Hamblin T.J., Stevenson F.K., Capra J.D. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 1992, 149:2337-2344.
16. Hargreaves D.C., Hyman P.L., Lu T.T., Ngo V.N., Bidgol A., Suzuki G., et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001, 194:45-56.
17. Muehlinghaus G., Cigliano L., Huehn S., Peddinghaus A., Leyendeckers H., Hauser A.E., et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005, 105:3965-3971.
18. Tokoyoda K., Zehentmeier S., Chang H., Radbruch A. Organization and maintenance of immunological memory by stroma niches. Eur J Immunol 2009, 39:2095-2099.
19. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nature 2005, 5:230-242.
20. Schaumann D.H.S., Tuischer J., Ebell W., Manz R.A., Lauster R. VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol 2007, 44:1606-1612.
21. Ingold K., Zumsteg A., Tardivel A., Huard B., Steiner Q., Cachero T.G., et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005, 201:1375-1383.
22. Cassesse G., Arce S., Hauser A.E., Lehnert K., Moewes B., Mostarac M., et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003, 171:1684-1690.
23. Diamanti A.P., Rosado M.M., Carsetti R., Valesini G. B cells in SLE: different biologic drugs for different pathogenic mechanisms. Autoimmun Rev 2007, 7:143-148.
24. Onodera T., Poe J.C., Tedder T.F., Tsubata T. CD22 regulates time course of both B cell division and antibody response. J Immunol 2008, 180:907-913.
25. Nitschke L., Flyd H., Ferguson D.J.P., Crocker P.R. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B Cells. J Exp Med 1999, 189:1513-1518.
26. Kallies A., Hasbold J., Fairfax K., Pridans C., Emslie D., McKenzie B.S., et al. Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 2007, 26:555-566.
27. Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney R., Boss J.M., et al. MTA3 and the Mi/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004, 119:75-86.
28. Sciammas R., Davis M.M. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. J Immunol 2004, 172:5427-5440.
29. Shaffer A.L., Lin K., Kuo T.C., Yu X., Hurt E.M., Rosenwald A., et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002, 17:51-62.
30. Lin F., Kuo H., Ying H., Yang F., Lin K. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation Proein-1 knockdown. Cancer Res 2007, 67:1914-1923.
31. Fairfax K.A., Corcoran L.M., Pridans C., Huntington N.D., Kallies A., Nutt S.L., et al. Different kinetics of Blimp-1 induction in B cells subsets revealed by reporter gene. J Immunol 2007, 178:4104-4111.
32. Shapiro-Shelef M., Lin K., Savitsky D., Liao J. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005, 202:1471-1476.
33. Knödel M., Kuss A.W., Lindemann D., Berberich I., Schimpl A. Reversal of Blimp-1-mediated apoptosis by A1, a member of the Bcl-2 family. Eur J Immunol 1999, 29:2988-2998.
34. Tomayko M.M., Cancro M.P. Long-lived B cells are distinguished by elevated expression of A1. J Immunol 1998, 160:107-111.
35. Shaffer A.L., Shapiro-Shelef M., Iwakoshi N.N., Lee A., Qian S., Zhao H., et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004, 21:81-93.
36. Iwakoshi N.N., Lee A., Vallabhajosyula P., Otipoby K.L., Rajewsky K., Glimcher L.H. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature 2003, 4:321-329.
37. Good K.L., Bryant V.L., Tangye S.G. Kinetics of human B cell behaviour and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006, 177:5236-5247.
38. Brandt K., Bulfone-Paus S., Foster D.C., Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003, 102:4090-4098.
39. Kuchen S., Robbins R., Sims G.P., Sheng C., Phillips T.M., Lipsky P.E., et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007, 179:5886-5896.
40. Konforte D., Simard N., Paige C.J. IL-21: an executor of B cell fate. J Immunol 2009, 182:1781-1787.
41. Sawalha A.H., Kaufman K.M., Kelly J.A., Adler A.J., Aberle T., Kilpatrick J., et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008, 67:458-461.
42. Bryant V.L., Ma C.S., Avery D.T., Li Y., GoodL K.L., Corcoran L.M., et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007, 179:8180-8190.
43. Arguni E., Tsuruoka N., Arima M., Sakamoto A., Hatano M., Tokuhisa T. Induction of high Bcl6 expression and its roles in germinal center B cells. Int Congr 2005, 1285:130-136.
44. Linterman M.A., Beaton L., Yu D., Ramiscal R.R., Srivastava M., Hogan J.J., et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 2010, 207:353-363.
45. Mackay F., Browning J.L. BAFF: a fundamental survival factor for B cells. Nature 2002, 2:465-475.
46. Huard B., Schneider P., Mauri D., Tschopp J., French L.A. T cell costimuation by the TNF ligand BAFF. J Immunol 2001, 167:6225-6231.
47. Ettinger R., Sims G.P., Robbins R., Withers D., Fischer R.T., Grammer A.C., et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007, 178:2872-2882.
48. Wang X.F., Yuan S.L., Jiang L., Zhang X.L., Li S.F., Guo Y., et al. Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance. Chin J Cell Mol Immunol 2007, 23:1041-1042.
49. Ettinger R., Sims G.P., Fairhurst A.M., Robbins R., Silva Y.S., Spolski R., et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005, 176:7867-7879.
50. Herber D., Brown T.P., Liang S., Young D.A., Collins M., Dunussi-Joannopoulus K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007, 178:3822-3830.
51. Bubier J.A., Bennett S.M., Sproule T.J., Lyons B.L., Olland S., Young D.A., et al. Treatment of BXSB-Yaa mice with IL-21R.Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann NY Acad Sci 2007, 1110:590-601.
52. Bubier J.A., Sproule T.J., Foreman O., Spolski R., Shaffer D.J., Morse H.C., et al. A critical role for IL-21 receptor signalling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 2009, 106:1518-1523.
53. Young D.A., Hegen M., Ma H.L., Whitters M.J., Albert L.M., Lowe L., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007, 56:1152-1163.
54. Jungel A., Distler J.H.W., Kurowska-Stolarska M., Seemayer C.A., Seibl R., Forster A., et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1468-1476.
55. Yuan S.L., Jiang L., Zhang X.L., Li S.F., Duan H.M., Wang X.F. Serum IL-21 level in patients with primary Sjögren's syndrome and clinical significance of IL-21. Chin J Cell Mol Immunol 2007, 23:124-126.
56. Odegard J.M., Marks B.R., DiPlacido L.D., Poholek A.C., Kono D.H., Dong C., et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med 2008, 205:2873-2886.
57. Iwai H., Abe M., Hirose S., Tsushima F., Tezuka K., Akiba H., et al. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 2003, 171:2848-2854.
58. Hutloff A., Bϋchner K., Reiter K., Baelde H.J., Odendahl M., Jacobi A., et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3211-3220.
59. Cortés M., Georgopoulos K. Aiolos Is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity. J Exp Med 2004, 199:209-219.
60. Baker K.P. BLyS - an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun Rev 2004, 3:368-375.
61. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005, 17:282-289.
62. Cancro M.P. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006, 65:34-36.
63. O'Connor B.P., Raman V.S., Erickson L.D., Cook W.J., Weaver L.K., Ahonen C., et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91-97.
64. Avery D.T., Kalled S.L., Ellyard J.I., Ambrose C., Bixler S.A., Thien M., et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297.
65. Cancro M.P., Cruz D.P., Khamashta A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009, 119:1066-1073.
66. Belnoue E., Pihlgren M., McGaha T.L., Tougne C., Rochat A., Bossen C., et al. APRIL is critical for plasmablast survival in bone marrow and poorly expressed in early-life bone marrow stromal cells. Blood 2008, 111:2755-2764.
67. Varfolomeev E., Kischkel F., Martin F., Seshasayee D., Wang H., Lawrence D., et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004, 24:997-1006.
68. Scholz J.L., Crowley J.E., Tomayko M.M., Steinel N., O'Neill P.J., Quinn W.J., et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008, 105:15517-15522.
69. Vallerskog T., Heimbϋrger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167.
70. Petri M., Stohl W., Chatham W., McCune W.J., Chevrier M., Ryel J., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
71. Zhao L.D., Li Y., Smith M.F., Wang J.S., Zhang W., Tang F.L., et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010, 19:1534-1549.
72. Collins C.E., Gavin A.L., Migone T., Hilbert D.M., Nemazee D., Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8:R6.
73. Cheema G.S., Roschke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319.
74. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005, 115:3083-3092.
75. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
76. Szodoray P., Jellestad S., Teague M.O., Jonsson R. Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome. Lab Invest 2003, 83:357-365.
77. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titer of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003, 62:168-171.
78. Varin M., Le Pottier L., Youinou P., Saulep D., Mackay F., Pers J. B-cell tolerance breakdown in Sjögren's Syndrome: Focus on BAFF. Autoimmun Rev 2010, 9:604-608.
79. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis. Arthritis Rheum 2006, 54:192-201.
80. Thangarajh M., Gomes A., Masterman T., Hillert J., Hjelmström P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004, 152:183-190.
81. Krumbholz M., Specks U., Wick M., Kalled S.L., Jenne D., Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005, 25:298-302.
82. Emmerich F., Bal G., Barakat A., Milz J., Mϋhle C., Martinez-Gamboa L., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2006, 136:309-314.
83. Migita K., Abiru S., Maeda Y., Nakamura M., Komori A., Ito M., et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007, 68:586-591.
84. Mackay I.R., Groom J., Mackay C.R. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 2002, 35:551-553.
85. Toubi E., Gordon S., Kessel A., Rosner I., Rozenbaum M., Shoenfeld Y., et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: Association with autoimmunity. J Autoimmun 2006, 27:134-139.
86. Roschke V., Sosnovtseva S., Ward C.D., Hong J.S., Smith R., Albert V., et al. BLyS and APRIL form biologically active heterodimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002, 169:4314-4321.
87. Tangye S., Bryant V.L., Cuss A.K., Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305-317.
88. Katsenelson N., Kanswal S., Puig M., Mostowski H., Verthelyi D., Akkoyunlu M. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 2007, 37:1785-1795.
89. Harigai M., Kawamoto M., Hara M., Kubota T., Kamatani N., Miyasaka N. Excessive production of IFN-{gamma} in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008, 181:2211-2219.
90. Scapini P., Nardelli B., Nadali G., Calzetti F., Pizzolo G., Montecucco C., et al. G-CSF stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003, 197:297-302.
91. Gavin A.L., Aït-Azzouzene D., Ware C.F., Namazee D. {Delta}BAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003, 278:38220-38228.
92. Youinou P., Pers J. The late news on BAFF in autoimmune diseases. Autoimmun Rev 2010, 9:804-806.
93. Gavin A.L., Duong B., Skog P., Aït-Azzouzene D., Greaves D.R., Scott M.L., et al. {Delta}BAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005, 175:319-328.
94. Emilie D., Mariette X. Interleukin 10 - a new therapeutic target in systemic lupus erythematosus?. Joint Bone Spine 2001, 68:4-5.
95. Wols M.H.A., Underhill G.H., Kansas G.S., Witte P.L. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002, 169:4213-4221.
96. Chevrier S., Genton C., Kallies A., Karnowski A., Otten L.A., Malissen B., et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci USA 2009, 106:3895-3900.
97. Blank M., Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun 2007, 28:62-68.
98. Stichweh D., Pascual V., Banchereau J. Recent advances in therapeutic strategies for SLE. Drug Discov Today Ther Strat 2006, 3:5-10.
99. García-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009, 8:343-348.
100. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005, 17:282-289.
101. Levesque M.C., Clair E.W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008, 121:13-21.
102. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8:515-519.
103. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
104. Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., Song X.Y.R. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006, 119:296-305.
105. Chong B.F., Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 2009, 13:1147-1153.